Expert Interviews

Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.

A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.

Insights on the role of circulating tumor DNA in treatment selection for patients with metastatic colorectal cancer.

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.

Centering focus on a second clinical scenario of metastatic hormone-sensitive prostate cancer, key opinion leaders identify treatment options based on variations in presentation.

Shared insight on strategies to monitor patient response to therapy and select second-line treatment when hormone-sensitive prostate cancer progresses.

Drs Sharyn Lewin and Ramez Eskander share their thoughts on comprehensive molecular testing for all women with endometrial cancer.

Expert oncologists discuss the evolving treatment landscape for diffuse large B-cell lymphoma (DLBCL).

Robert Coleman, MD, FACOG, FACS, reviews data from a study investigation the frequency of molecular testing in patients with endometrial cancer.

Andre H. Goy, MD, and Andrew Ip, MD, offer insights on the future of mantle cell lymphoma treatment.

Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.

A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.

Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.

Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.

Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,

Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.

Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.

Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.